1383801-08-8

Basic information

• Product Name: (S,S)-2-methyl-N-(3-methyl-1-{4-[5-(trifluoromethyl)pyridin-2-yl]phenyl}butyl)propane-2-sulfinamide
• Synonyms: (S,S)-2-methyl-N-(3-methyl-1-{4-[5-(trifluoromethyl)pyridin-2-yl]phenyl}butyl)propane-2-sulfinamide
• CAS NO: 1383801-08-8
• Molecular Weight: 412.519
• Mol File: 1383801-08-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (S,S)-2-methyl-N-(3-methyl-1-{4-[5-(trifluoromethyl)pyridin-2-yl]phenyl}butyl)propane-2-sulfinamide(CAS DataBase Reference)
• NIST Chemistry Reference: (S,S)-2-methyl-N-(3-methyl-1-{4-[5-(trifluoromethyl)pyridin-2-yl]phenyl}butyl)propane-2-sulfinamide(1383801-08-8)
• EPA Substance Registry System: (S,S)-2-methyl-N-(3-methyl-1-{4-[5-(trifluoromethyl)pyridin-2-yl]phenyl}butyl)propane-2-sulfinamide(1383801-08-8)

Safety Data

• Hazardous Substances Data: 1383801-08-8(Hazardous Substances Data)

Upstream product

• 871252-64-1 4-(5-(trifluoromethyl)pyridin-2-yl)benzaldehyde 
• 87199-17-5 4-formylphenylboronic acid, 
• 52334-81-3 2-chloro-5-trifluoromethylpyridine 

Downstream Products

• 1383801-20-4 (S)-ethyl N-({6-[(3-methyl-1-{4-[5-(trifluoromethyl)pyridin-2-yl]phenyl}butyl)amino]pyridin-3-yl}carbonyl)-beta-alaninate 
• 1383801-14-6 (S)-methyl 6-[(3-methyl-1-{4-[5-(trifluoromethyl)pyridin-2-yl]phenyl}butyl)amino]nicotinate 
• 1383801-17-9 (S)-6-[(3-methyl-1-{4-[5-(trifluoromethyl)pyridin-2-yl]phenyl}butyl)amino]nicotinic acid 
• 1383801-11-3 (S)-3-methyl-1-{4-[5-(trifluoromethyl)pyridin-2-yl]phenyl}butan-1-amine 
• 1383801-02-2 (S)-N-({6-[(3-methyl-1-{4-[5-(trifluoromethyl)pyridin-2-yl]phenyl}butyl)amino]pyridin-3-yl}carbonyl)-β-alanine 

Relevant articles and documents

Glucagon Receptor Modulators

The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.